所有血浆都一样吗?供者间变异性影响的初步研究
该初步研究先以24名随机供者血浆孵育肺内皮细胞,测定跨内皮电阻,筛选出保护性强与保护性弱的血浆单位。随后在小鼠剖腹失血性休克模型中,分别用上述两种血浆复苏,并与不复苏及假手术组比较。保护性强的血浆组跨内皮电阻显著高于保护性弱的血浆组(0.801±0.022 vs 0.744±0.035,p=0.002),保护性弱的血浆组syndecan-1显著升高(38427±1257 vs 231±172 pg/mL,p<0.001)。体内实验中,保护性强的血浆减轻肺组织病理损伤(1.56±0.27 vs 2.33±0.47,p=0.005),降低髓过氧化物酶(2.590±0.559 vs 6.045±1.885,p=0.02),并增加肺syndecan-1免疫染色(20.909±8.202 vs 9.325±3.412,p=0.018)。作者认为供者间血浆变异性可能对基于血浆的复苏产生重要临床影响。
要点
- 24名随机供者血浆逆转内皮单层高通透性的能力存在差异,保护性强组跨内皮电阻0.801±0.022 vs 保护性弱组0.744±0.035(p=0.002)。
- 保护性弱的血浆组syndecan-1显著高于保护性强的血浆组(38427±1257 vs 231±172 pg/mL,p<0.001)。
- 小鼠失血性休克模型中,保护性强的血浆肺组织病理损伤评分低于保护性弱的血浆(1.56±0.27 vs 2.33±0.47,p=0.005)。
- 保护性强的血浆组髓过氧化物酶低于保护性弱的血浆组(2.590±0.559 vs 6.045±1.885,p=0.02)。
- 保护性强的血浆组肺syndecan-1免疫染色高于保护性弱的血浆组(20.909±8.202 vs 9.325±3.412,p=0.018)。
适用人群与场景
- 体外实验使用24名随机供者的血浆孵育肺内皮细胞。
- 体内实验使用小鼠剖腹失血性休克模型,复苏时选用体外筛选出的保护性强或保护性弱的血浆单位,并与不复苏组及假手术组比较。
研究设计与关键结果
- 初步研究:体外用24名随机供者血浆孵育肺内皮细胞测跨内皮电阻,保护性强血浆跨内皮电阻显著高于保护性弱血浆(0.801±0.022 vs 0.744±0.035,p=0.002)。
- 保护性弱血浆组syndecan-1显著高于保护性强血浆组(38427±1257 vs 231±172 pg/mL,p<0.001),细胞因子组间有差异。
- 小鼠剖腹失血性休克后,保护性强血浆组肺组织病理损伤评分低于保护性弱血浆组(1.56±0.27 vs 2.33±0.47,p=0.005)。
- 保护性强血浆组髓过氧化物酶低于保护性弱血浆组(2.590±0.559 vs 6.045±1.885,p=0.02)。
- 保护性强血浆组肺syndecan-1免疫染色高于保护性弱血浆组(20.909±8.202 vs 9.325±3.412,p=0.018)。
证据类型、等级与局限
- 证据类型:体外细胞实验联合小鼠在体初步研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为供者间血浆变异性可能对失血性休克基于血浆的复苏的保护作用产生不利影响,并可能对患者安全和临床结局有重要意义。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Clinical benefits of plasma as an adjunct for treatment of hemorrhagic shock (HS) have been well established. However, its use is not without risk. Little is understood regarding the clinical implications of plasma variability. We hypothesized there to be interdonor variability in plasma that would impact endothelial and organ function postinjury.
METHODS: Pulmonary endothelial cells (ECs) were incubated with plasma from 24 random donors, and transendothelial electrical resistance was measured. Plasma units with a more or less protective effect on reducing EC permeability were selected for testing in vivo. Syndecan-1 and cytokines were measured. Mice underwent laparotomy and then HS followed by resuscitation with the selected plasma units and were compared with mice receiving no resuscitation and shams. Lung tissue was sectioned and stained for myeloperoxidase and pulmonary syndecan-1 and scored for lung histopathologic injury.
RESULTS: Plasma from 24 donors revealed variability in the reversal of EC monolayer hyperpermeability; transendothelial electrical resistance for the more protective plasma was significantly higher than that for the less protective plasma (0.801 ± 0.022 vs. 0.744 ± 0.035; p = 0.002). Syndecan-1 was also markedly increased in the less protective compared with the more protective plasma (38427 ± 1257 vs. 231 ± 172 pg/mL, p < 0.001), while cytokines varied. In vivo, the more protective plasma mitigated lung histopathologic injury compared with the less protective plasma (1.56 ± 0.27 vs. 2.33 ± 0.47, respectively; p = 0.005). Similarly, myeloperoxidase was significantly reduced in the more protective compared with the less protective plasma group (2.590 ± 0.559 vs. 6.045 ± 1.885; p = 0.02). Lastly, pulmonary syndecan-1 immunostaining was significantly increased in the more protective compared with the less protective plasma group (20.909 ± 8.202 vs. 9.325 ± 3.412; p = 0.018).
CONCLUSION: These data demonstrate significant interdonor variability in plasma that can adversely influence the protective effects of plasma-based resuscitation on HS-induced lung injury. This may have important implications for patient safety and clinical outcomes.
参考来源
- Chipman AM, Pati S, Potter D, et al. Is all plasma created equal? A pilot study of the effect of interdonor variability. J Trauma Acute Care Surg. 2020. PMID: 31688783. doi:10.1097/TA.0000000000002529
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。